comprehensive -WSS

comprehensive

author：comprehensive 2025-09-27 09:45:38 - browse：84698

Sammy Kimball for STAT

Can Novavax finally get it right? What’s a “triple-G” drug? And is Novo Nordisk losing ground?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Elaine Chen joins us to explain how the era of Wegovy could be short-lived in light of powerful new weight-loss medicines from Eli Lilly. Then, John Jacobs, the new CEO of Novavax, stops by to explain his plan to right the ship at a company that has struggled to make the most of its potent Covid-19 vaccine.

For more on what we cover, here’s the news on Lilly; here’s more on Novavax; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Affirmative action in medical school literally saved lives
Next article： ALS patient reclaims some autonomy thanks to wearable 'robot'

WSS

California wildfire smoke linked to 52,000 early deaths, study says

Health care court cases: Humana, Sutter, Novant

Man killed during FBI raid in connection with threats against Biden, other officials

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

Man killed during FBI raid in connection with threats against Biden, other officials

knowledge

comprehensive

Wikipedia

Wildfire smoke exposes gaps in outdoor worker protections

Drastic changes should bring profitability, startup health insurers say

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Statins may not be needed by millions of people, study suggests

Medicare proposal to cover medical devices draws a mixed reaction

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Medicare proposal to cover medical devices draws a mixed reaction

My daughter's legacy lives on through her writing, phage therapy

Affirmative action in medical school literally saved lives

A biotech analyst on neuroscience, placebo effect, not over

focus

NIH tests clinical research in primary care with $30 million program

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

New report analyzes digital physical therapy solutions' effectiveness

Wegovy’s successful heart trial raises vital question about weight loss

Methadone doses haven’t kept up in the age of fentanyl

Health care court cases: Humana, Sutter, Novant

focus

leisure time

leisure time

focus